In a 2014 study Bollard et al. looked at LMP1/2 specific EBV-CTLs in patients with a variety of latency II associated malignancy including Hodgkin lymphoma, DLBCL, T/NK cell lymphomas, and NPC. This evidence concerns the gene PDLIM7 and Hodgkins lymphoma.